Índice Bovespa

US Dollar vs BRL

As Melhores Corretoras Online

Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.

Cadastre-se

AUTL Autolus Therapeutics PLC

1,9201

-0,0399 (-2,04%)

Pré-mercado

Última atualização: 10:00:01

Atrasado em 15 minutos

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Date of Notice

09/16/2024

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

06/14/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ J.P. Morgan Securities LLC as agent and attorney-in-fact for Martin Pule

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Autolus Therapeutics (NASDAQ:AUTL)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025

Click aqui para mais gráficos Autolus Therapeutics.

Autolus Therapeutics (NASDAQ:AUTL)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025

Click aqui para mais gráficos Autolus Therapeutics.

Notícias Autolus Therapeutics PLC

Autolus Therapeutics Presents Clinical Data Updates at the 2025 Tandem Meetings
Sexta, 17 de Janeiro de 2025 (1 mês atrás) • GlobeNewswire Inc.

Autolus Therapeutics Provides Business Updates and 2025 Overview
Segunda, 13 de Janeiro de 2025 (1 mês atrás) • GlobeNewswire Inc.

Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024
Segunda, 9 de Dezembro de 2024 (3 meses atrás) • GlobeNewswire Inc.

Autolus Therapeutics Announces Publication of Data from the FELIX study of obe-cel in r/r Adult B-ALL Patients in The New England Journal of Medicine
Segunda, 2 de Dezembro de 2024 (3 meses atrás) • GlobeNewswire Inc.

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Quinta, 14 de Novembro de 2024 (3 meses atrás) • Edgar (US Regulatory)

Form S-8 - Securities to be offered to employees in employee benefit plans
Quinta, 14 de Novembro de 2024 (3 meses atrás) • Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Quinta, 14 de Novembro de 2024 (3 meses atrás) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Terça, 12 de Novembro de 2024 (3 meses atrás) • Edgar (US Regulatory)

Form 8-K - Current report
Terça, 12 de Novembro de 2024 (3 meses atrás) • Edgar (US Regulatory)

Autolus Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates
Terça, 12 de Novembro de 2024 (3 meses atrás) • GlobeNewswire Inc.

Form 8-K - Current report
Terça, 12 de Novembro de 2024 (3 meses atrás) • Edgar (US Regulatory)

Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)
Sexta, 8 de Novembro de 2024 (4 meses atrás) • GlobeNewswire Inc.

Mais Notícias de Autolus Therapeutics PLC

Índice Bovespa

Oncoclinicas Brasil Serv... ON

PÃO DE AÇUCAR ON

Brava Energia ON

Azevedo & Travassos Ener... ON

HOTEIS OTHON PN

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições